Fig. 3: Pan-antiviral activity of GZNL-P36 against SARS-CoV-2 variants and other coronavirus. | Nature Communications

Fig. 3: Pan-antiviral activity of GZNL-P36 against SARS-CoV-2 variants and other coronavirus.

From: Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19

Fig. 3: Pan-antiviral activity of GZNL-P36 against SARS-CoV-2 variants and other coronavirus.

a Enzymatic maximum inhibition efficacy of GZNL-P36 against coronaviruses PLpro. b The phylogenetic tree of coronaviruses PLpro used in this experiment (Shang, J. (2024) BioRender.com/b84m836). Antiviral activity of GZNL-P36 against SARS-CoV-2 wild type (WT) (c), variants Omicron BA.5 (d), and XBB.1 (e). Vero E6 cells were pre-treated with indicated compounds with different concentrations for 1 h and then infected with SARS-CoV-2 wild type (WT), variants Omicron BA.5, and XBB.1 at an MOI of 0.01. The EC50 was assessed after being cultured for three days. f The representative inhibition curves of GZNL-P36 against HCoV-229E and HCoV-OC43 in Huh-7 cells. The EC50 was assessed after being cultured for two days. Data are presented as mean of two (HCoV-NL63 in f) or mean ± s.d. of three (a, c, d, e, and HCoV-OC43 and HCoV-OC229E in f) technical replicates. The error bars are mean ± s.d. Three independent experiments were tested and shown in Supplementary Table 5, only one representative is shown here. Source data are provided as a Source Data file.

Back to article page